CLAIMS

1. An organic concentrate composition comprising:

(a) Compound A which is 2-{[5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-*d*]pyrimidin-4-yl]oxy}-3-(2-{[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy}phenyl)propanoic acid, or a pharmaceutically acceptable salt thereof,

(b) a negatively charged or polar phospholipid stabiliser, and

(c) a stabiliser against jellification.

2. The organic concentrate composition according to claim 1, wherein Compound A is (2*R*)-2-{[(5S_a)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-*d*]pyrimidin-4-yl]oxy}-3-(2-{[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy}phenyl)propanoic acid, or a pharmaceutically acceptable salt thereof.

3. The organic concentrate composition according to claim 1, wherein Compound A is the free molecule.

4. The organic concentrate composition according to claim 1, wherein the negatively charged or polar phospholipid stabiliser is selected from DMPG sodium or ammonium salt (1,2-Dimyristoyl-sn-glycero-3-phospho-rac-glycerol, or dimyristoyl phosphatidylglycerol), POPG sodium salt (1-Palmitoyl-2-oleoyl-sn-glycero-3[Phospho-rac-(1-glycerol)]), DOPS sodium salt (1,2-Dioleoyl-sn-glycero-3-phosphoserine), DOPG sodium salt (1,2-Dioleoyl-sn-glycero-3[Phospho-rac-(1-glycerol)]), DPPG (1,2-Dipalmitoyl-sn-glycero-3[Phospho-rac-(1-glycerol)]) sodium or ammonium salt, DSPG (1,2-Distearoyl-sn-glycero-3[Phospho-rac-(1-glycerol)]) sodium or ammonium salt, soy phosphatidic acid (PA) sodium salt, egg phosphatidic acid (PA) sodium salt, soy phosphatidylserine (PS) sodium salt, egg phosphatidylglycerol (PG) sodium salt, soy phosphatidylglycerol (PG) sodium salt, phosphatidyl inositol (PI) sodium salt, egg lecithin, soy lecithin, and sodium oleate.

5. The organic concentrate composition according to claim 4, wherein the negatively charged or polar phospholipid stabiliser is 1,2-Dimyristoyl-sn-glycero-3-phospho-rac-glycerol, sodium or ammonium salt, egg lecithin, or soy lecithin.

6. The organic concentrate composition according to claim 1, wherein the stabiliser against jellification is a polymer or an electrolyte.

7. The organic concentrate composition according to claim 1, wherein the stabiliser against jellification is an electrolyte selected from sodium chloride, potassium chloride, sodium phosphate di- and monobasic, ammonium sulphate and arginine.

8. The organic concentrate composition according to claim 1, wherein the stabiliser against jellification is sodium chloride.

9. The organic concentrate composition according to claim 1, wherein the stabiliser against jellification is a polymer selected from PEG300 and PEG400.


10. The organic concentrate composition according to claim 1, further comprising a solvent.

11. The organic concentrate composition according to claim 10, wherein the solvent is selected from propylene glycol, ethanol, and/or mixtures thereof.

12. A pharmaceutical composition comprising a mixture of the organic concentrate composition according to claim 1 and a liposomal vehicle, wherein the liposomal vehicle comprises a phospholipid and a tonicity adjusting agent.

13. The pharmaceutical composition according to claim 12, wherein the phospholipid is selected from egg lecithin, soy lecithin, and synthetic phospholipids.

14. The pharmaceutical composition according to claim 12, wherein the phospholipid is of the formula



(I)

wherein

- R_1 represents C_{10}-C_{24}acyl;
- R_2 represents C_{10}-C_{24}acyl;
- R_3 represents hydrogen, 2-trimethylamino-1-ethyl, 2-amino-1-ethyl, C_1-C_4alkyl, C_1-C_5alkyl substituted by carboxy, C_2-C_5alkyl substituted by carboxy and hydroxy, C_2-C_5alkyl substituted by carboxy and amino, an inositol group or a glyceryl group;

or a salt of such compound.

15. The pharmaceutical composition according to claim 12, wherein the phospholipid is selected from egg lecithin, soy lecithin, POPC (palmitoyl oleoyl phosphatidylcholine), DOPC (1,2-Dioleoyl-sn-glycero-3-phosphocholine), and DMPC (1,2-Dimyristoyl-sn-glycero-3-phosphocholine).

16. The pharmaceutical composition according to claim 12, wherein the phospholipid is egg lecithin or soy lecithin comprising at least 70 % phosphatidylcholine.

17. The pharmaceutical composition according to claim 12, wherein the tonicity adjusting agent is selected from dextrose, glucose, mannitol, sucrose, lactose, trehalose, glycerine and NaCl.

18. A liposomal pharmaceutical composition comprising, in addition to liposomes:
(a) Compound A which is 2-{[5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-*d*]pyrimidin-4-yl]oxy}-3-(2-{[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy}phenyl)propanoic acid, or a pharmaceutically acceptable salt thereof; and
(b) a stabiliser against jellification.

19. The liposomal pharmaceutical composition according to claim 18, comprising:
(a) Compound A which is (2*R*)-2-{[(5S_a)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-*d*]pyrimidin-4-yl]oxy}-3-(2-{[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy}phenyl)propanoic acid, or a pharmaceutically acceptable salt thereof, and
(b) a stabiliser against jellification, which is a polymer or an electrolyte.

20. The liposomal pharmaceutical composition according to claim 19, wherein Compound A is the free molecule.

21. The liposomal pharmaceutical composition according to claim 19, wherein the stabiliser against jellification is an electrolyte selected from sodium chloride, potassium chloride, sodium phosphate di- and monobasic, ammonium sulphate and arginine.

22. The liposomal pharmaceutical composition according to claim 19, wherein the stabiliser against jellification is sodium chloride.

23. The liposomal pharmaceutical composition according to claim 19, wherein the stabiliser against jellification is a polymer selected from PEG300 and PEG400.

24. The liposomal pharmaceutical composition according to claim 18, further comprising a negatively charged or polar phospholipid stabiliser.

25. The liposomal pharmaceutical composition according to claim 24, wherein the negatively charged or polar phospholipid stabiliser is selected from DMPG sodium or ammonium salt (1,2-Dimyristoyl-sn-glycero-3-phospho-rac-glycerol, or dimyristoyl phosphatidylglycerol), POPG sodium salt (1-Palmitoyl-2-oleoyl-sn-glycero-3[Phospho-rac-(1-glycerol)]), DOPS sodium salt (1,2-Dioleoyl-sn-glycero-3-phosphoserine), DOPG sodium salt (1,2-Dioleoyl-sn-glycero-3[Phospho-rac-(1-glycerol)]), DPPG (1,2-Dipalmitoyl-sn-glycero-3[Phospho-rac-(1-glycerol)]) sodium or ammonium salt, DSPG (1,2-Distearoyl-sn-glycero-3[Phospho-rac-(1-glycerol)]) sodium or ammonium salt, soy phosphatidic acid (PA) sodium salt, egg phosphatidic acid (PA) sodium salt, soy phosphatidylserine (PS) sodium salt, egg phosphatidylglycerol (PG) sodium salt, soy phosphatidylglycerol (PG) sodium salt, phosphatidyl inositol (PI) sodium salt, egg lecithin, soy lecithin, and sodium oleate.

26. The liposomal pharmaceutical composition according to claim 24, wherein the negatively charged or polar phospholipid stabiliser is selected from 1,2-Dimyristoyl-sn-glycero-3-phospho-rac-glycerol, sodium or ammonium salt, egg lecithin, and soy lecithin.


27. The liposomal pharmaceutical composition according to claim 18, further comprising a

solvent.

28. The liposomal pharmaceutical composition according to claim 27, wherein the solvent is selected from propylene glycol, ethanol, and/or mixtures thereof.

29. The liposomal pharmaceutical composition according to claim 18, wherein the liposome comprises a phospholipid selected from egg lecithin, soy lecithin, and synthetic phospholipids.

30. The liposomal pharmaceutical composition according to claim 29, wherein the phospholipid is of the formula



(I)

wherein

- R_1 represents C_{10}-C_{24}acyl;
- R_2 represents C_{10}-C_{24}acyl;
- R_3 represents hydrogen, 2-trimethylamino-1-ethyl, 2-amino-1-ethyl, C_1-C_4alkyl, C_1-C_5alkyl substituted by carboxy, C_2-C_5alkyl substituted by carboxy and hydroxy, C_2-C_5alkyl substituted by carboxy and amino, an inositol group or a glyceryl group;

or a salt of such compound.

31. The liposomal pharmaceutical composition according to claim 29, wherein the phospholipid is selected from egg lecithin, soy lecithin, POPC (palmitoyl oleoyl phosphatidylcholine), DOPC (1,2-Dioleoyl-sn-glycero-3-phosphocholine), and DMPC (1,2-Dimyristoyl-sn-glycero-3-phosphocholine).

32. The liposomal pharmaceutical composition according to claim 29, wherein the phospholipid is egg lecithin or soy lecithin comprising at least 70 % phosphatidylcholine.

33. The liposomal pharmaceutical composition according to claim 18, further comprising a tonicity adjusting agent.

34. The liposomal pharmaceutical composition according to claim 33, wherein the tonicity adjusting agent is selected from dextrose, glucose, mannitol, sucrose, lactose, trehalose, glycerine and NaCl.

35. Use of the organic concentrate composition according to Claim 1 in the manufacture of a medicament for the treatment of cancer in a subject in need thereof, wherein an effective amount of the organic concentrate composition is to be administered to the subject.

36. Use of the pharmaceutical composition according to Claim 12 in the manufacture of a medicament for the treatment of cancer in a subject in need thereof, wherein an effective amount of the pharmaceutical composition is to be administered to the subject.

37. Use of the liposomal pharmaceutical composition according to Claim 18 in the manufacture of a medicament for the treatment of cancer in a subject in need thereof, wherein an effective amount of the liposomal pharmaceutical composition is to be administered to the subject.

38. A combination comprising
(a) the pharmaceutical composition according to claim 12, and
(b) one or more therapeutically active agents, for simultaneous, sequential or separate use.

39. A combination comprising:
(a) the pharmaceutical composition according to claim 18, and
(b) one or more therapeutically active agents, for simultaneous, sequential or separate use.

40. A kit comprising:
(a) a liposomal vehicle and
(b) the organic concentrate composition according to claim 1.

41. The use according to claim 36, wherein the cancer is selected from cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, œsophagus

and liver, lymphoblastic leukaemias, acute myeloid leukaemia, lymphomas, non-Hodgkin's B-cell lymphoma, diffuse large B-cell lymphoma, melanomas, malignant haemopathies, myelodysplastic syndrome, myelomas, multiple myeloma, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.

42. The use according to claim 37, wherein the cancer is selected from cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, œsophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemia, lymphomas, non-Hodgkin's B-cell lymphoma, diffuse large B-cell lymphoma, melanomas, malignant haemopathies, myelodysplastic syndrome, myelomas, multiple myeloma, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.